Analytical Data
-
Gene name
GCSF
- Application
-
Alternative Names
CSF3; G-CSF; Granulocyte Colony Stimulating Factor; Pluripoietin; Filgrastim; Lenograstim
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P09919
-
Expression Region
Ala30~Pro207
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Granulocyte colony-stimulating factor (GCSF) is a crucial cytokine that plays a significant role in hematopoiesis, particularly in the stimulation and differentiation of neutrophil progenitor cells in the bone marrow. The therapeutic use of recombinant GCSF has gained prominence, particularly in the management of chemotherapy-induced neutropenia, which is a common complication in cancer patients that increases the risk of infections. By promoting the proliferation and maturation of neutrophils, GCSF helps in restoring the immune response and reducing the incidence of febrile neutropenia, thereby improving patient outcomes and potentially allowing for the continuation of chemotherapy regimens. Furthermore, research into the structure and function of GCSF has led to a deeper understanding of its receptor interactions and signaling pathways, paving the way for the development of novel therapeutic strategies. Beyond its application in oncology, GCSF is being explored for its potential benefits in other areas, such as bone marrow mobilization for stem cell transplants and treatment of certain autoimmune disorders. As ongoing studies continue to elucidate the diverse roles of GCSF in the immune system, its recombinant form remains a vital component in clinical practice, highlighting its significance in both therapeutic settings and deeper immunological research.
